Last reviewed · How we verify
Calderasib OCT — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Calderasib OCT (Calderasib OCT) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Calderasib OCT TARGET | Calderasib OCT | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Calderasib OCT CI watch — RSS
- Calderasib OCT CI watch — Atom
- Calderasib OCT CI watch — JSON
- Calderasib OCT alone — RSS
Cite this brief
Drug Landscape (2026). Calderasib OCT — Competitive Intelligence Brief. https://druglandscape.com/ci/calderasib-oct. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab